Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Small study to uncover how exercise changes Liver's sugar output in diabetes

NCT ID NCT06993454

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 13, 2026 · Updated 3 times

Summary

This study looks at how exercise changes the amount of sugar the liver makes in people with type 2 diabetes and fatty liver disease. Researchers will measure liver sugar production during rest and exercise in 12 adults aged 25-55. The goal is to better understand how exercise helps control blood sugar in these conditions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help explain how exercise improves blood sugar control in people with type 2 diabetes and fatty liver.
What could go wrong
This is a very small, early-stage observational study with only 12 participants. It is not testing a treatment, so it may not lead to direct medical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 12 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2025

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 to 55 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria for individuals with T2D and elevated liver fat ≥5.6% 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Male or (pre-menopausal) female, aged 25-55 years 4. Body mass index (BMI) between 25 and 45 kg/m2 5. Sedentary (1 day or less per week of structured exercise) 6. Type 2 diabetes mellitus: HbA1c ≥7.5% 7. Liver fat ≥5.6% based on MRI 8. Weight stable (± 2 kg) for prior 3 months Inclusion criteria for lean, healthy controls 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Male or (pre-menopausal) female, aged 25-55 years 4. Body mass index (BMI) between 18.5 and 27.5 kg/m2 5. Normal liver fat (FibroScan CAP \<249dB/m, \<5.6% liver fat based on MRI) 6. Weight stable (± 2 kg) for prior 3 months 7. Active (≥3 day/week of structured exercise) Exclusion Criteria 1. Exclusion criteria for individuals with T2D and elevated liver fat ≥5.6% Currently taking insulin, incretin mimetics, and/or thiazolidinediones 2. Any change in glucose-lowering medications within the previous three months. 3. Inability to stop any medications which interfere with glucose metabolism for visits 4 and 7. 4. Resting blood pressure ≥ 160/100 mm Hg 5. Triglycerides ≥ 500 mg/dL 6. Any renal, cardiac, liver, lung, or neurological disease that in the opinion of the principal investigator would compromise participant safety or the participants' ability to complete the exercise protocol 7. Any significant disease or unstable medical condition (i.e., coronary heart disease, chronic renal failure, chronic hepatic disease, severe pulmonary disease) 8. Presence of clinically significant abnormalities on electrocardiogram (ECG) that is a contra-indication to exercise testing 9. Cancer (active malignancy with or without concurrent chemotherapy; except for basal cell carcinoma) 10. Pregnancy during the previous 6 months, lactating, or planned pregnancy in the next 6 months 11. Post- or peri-menopausal women 12. Partial and/or full hysterectomy (self-report) 13. Use of drugs known to affect energy metabolism or body weight: including, but not limited to orlistat, sibutramine, ephedrine, phenylpropanolamine, corticosterone, etc 14. Hyperthyroidism including those with normal TSH (0.35-4.5) on pharmacological treatment; individuals with hypothyroidism may be referred to their primary care provider for evaluation and retested; any medication change for hypothyroidism must be stable for ≥3 months prior to retesting 15. Current treatment with blood thinners or anti-platelet medications that cannot be safely stopped for testing procedures 16. New onset (\<3 months on a stable regime) hormone replacement therapy 17. Current use of beta-adrenergic blocking agents 18. Major surgery on the abdomen, pelvis, or lower extremities within previous 3 months 19. Previous bariatric or other surgery for obesity 20. Abnormal blood count/anemia (hemoglobin \<12 g/dl in men or 11 g/dl in women; Hct \<34%), blood transfusion or blood donation within the last 2 months 21. Current smokers (smoking within the past 3 months prior to screening visit, including any/all tobacco products) 22. Current drug or alcohol abuse/dependence, or positive urine toxicology screen 23. Alcohol consumption \>7 drinks per week for women or 14 drinks per week for men or history of binge drinking (≥5 drinks for males or 4 drinks for females in a 2-hour period more than once per month) 24. Metal implants (pacemaker, aneurysm clips) based on investigator's judgment at screening 25. Not physically capable of performing the exercise required of the study protocols 26. Unable to participate in Magnetic Resonance Imaging (MRI) assessments due to physical limitations of equipment tolerances (e.g. MRI bore size) based on investigator's judgment at screening. 27. Unable to tolerate MRI or claustrophobia. 28. Diagnosed psychotic or psychiatric conditions prohibiting adherence to study protocol; hospitalization for any psychotic or psychiatric condition within one year 29. Self-reported chronic, active, or latent infection requiring chronic antibiotic or anti-viral treatment; Human Immunodeficiency Virus (HIV); active hepatitis B or C undergoing antiviral therapy 30. Unable or unwilling to communicate with staff or to provide written informed consent Exclusion criteria for lean, healthy controls 1. Currently taking insulin, injectable incretin mimetics, and/or thiazolidinediones 2. Taking glucose-lowering medications 3. HbA1c ≥ 5.7%; pre-diabetes, type 2 diabetes, or type 1 diabetes 4. Resting blood pressure ≥ 160/100 mm Hg 5. Triglycerides ≥ 500 mg/dL 6. Any renal, cardiac, liver, lung, or neurological disease that in the opinion of the principal investigator would compromise participant safety or the participants' ability to complete the exercise protocol 7. Any significant disease or unstable medical condition (i.e., coronary heart disease, chronic renal failure, chronic hepatic disease, severe pulmonary disease) 8. Presence of clinically significant abnormalities on electrocardiogram (ECG) that is a contra-indication to exercise testing 9. Cancer (active malignancy with or without concurrent chemotherapy; except for basal cell carcinoma) 10. Pregnancy during the previous 6 months, lactating, or planned pregnancy in the next year 11. Post- or peri-menopausal women 12. Partial and/or full hysterectomy (self-report) 13. Use of drugs known to affect energy metabolism or body weight: including, but not limited to orlistat, sibutramine, ephedrine, phenylpropanolamine, corticosterone, etc 14. Hyperthyroidism including those with normal TSH (0.35-4.5) on pharmacological treatment; individuals with hypothyroidism may be referred to their primary care provider for evaluation and retested; any medication change for hypothyroidism must be stable for ≥3 months prior to retesting 15. Current treatment with blood thinners or anti-platelet medications that cannot be safely stopped for testing procedures 16. New onset (\<3 months on a stable regime) hormone replacement therapy 17. Current use of beta-adrenergic blocking agents 18. Major surgery on the abdomen, pelvis, or lower extremities within previous 3 months 19. Previous bariatric or other surgery for obesity 20. Increased liver function tests (AST/ALT/GGT/or alkaline phosphatase greater than 2.5 times the upper limit of normal) 21. Abnormal blood count/anemia (hemoglobin \<12 g/dl in men or 11 g/dl in women; Hct \<34%), blood transfusion or blood donation within the last 2 months 22. Current smokers (smoking within the past 3 months prior to screening visit, including any/all tobacco products) 23. Current drug or alcohol abuse/dependence, or positive urine toxicology screen 24. Alcohol consumption \>7 drinks per week for women or 14 drinks per week for men or history of binge drinking (≥5 drinks for males or 4 drinks for females in a 2-hour period more than once per month) 25. Metal implants (pacemaker, aneurysm clips) based on investigator's judgment at screening 26. Not physically capable of performing the exercise required of the study protocols 27. Unable to participate in Magnetic Resonance Imaging (MRI) assessments due to physical limitations of equipment tolerances (e.g. MRI bore size) based on investigator's judgment at screening. 28. Unable to tolerate MRI or claustrophobia. 29. Diagnosed psychotic or psychiatric conditions prohibiting adherence to study protocol; hospitalization for any psychotic or psychiatric condition within one year 30. Self-reported chronic, active, or latent infection requiring chronic antibiotic or anti-viral treatment; Human Immunodeficiency Virus (HIV); active hepatitis B or C undergoing antiviral therapy 31. Unable or unwilling to communicate with staff or to provide written informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatic steatosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AdventHealth Translational Research Institute

    RECRUITING

    Orlando, Florida, 32804, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.